Sunshine Biopharma Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.3M | $8.1M | $8.6M | $9.4M | $9.4M | $8.9M | $9.6M | $8.4M |
| Cost of Revenue | $6.8M | $5.9M | $5.5M | $6.3M | $6.0M | $6.2M | $6.5M | $5.6M |
| Gross Profit | $2.4M | $2.2M | $3.0M | $3.1M | $3.4M | $2.7M | $3.1M | $2.9M |
| Gross Margin | 26.2% | 27.0% | 35.3% | 32.6% | 36.4% | 30.7% | 32.2% | 34.0% |
| Operating Expenses | ||||||||
| Research & Development | $13.2K | $31.7K | $73.5K | $119.3K | $196.2K | $215.3K | $149.3K | $126.4K |
| SG&A Expense | $4.0M | $3.6M | $4.8M | $4.2M | $5.5M | $4.0M | $5.2M | $4.0M |
| Operating Income | $-1.6M | $-1.4M | $-1.8M | $-1.1M | $-2.1M | $-1.3M | $-2.1M | $-1.1M |
| Operating Margin | -17.4% | -17.3% | -20.9% | -11.5% | -21.8% | -14.6% | -21.7% | -13.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-1.6M | $-1.2M | $-1.7M | $-1.0M | $-2.0M | $-1.2M | $-2.3M | $-982.6K |
| Income Tax Expense | $0 | $0 | $408.4K | $-137.4K | $-209.2K | $-40.2K | $-128.7K | $215.2K |
| Net Income | $-1.6M | $-1.2M | $-2.1M | $-883.8K | $-1.8M | $-1.2M | $-2.2M | $-1.2M |
| Net Margin | -16.9% | -15.4% | -25.0% | -9.4% | -18.8% | -13.3% | -22.5% | -14.2% |
| EPS (Basic) | $-1.15 | $-0.25 | $3.13 | $-0.03 | $-0.66 | $-0.07 | $0.93 | $-0.16 |
| EPS (Diluted) | — | — | — | — | $-0.14 | $-0.07 | — | — |
| Shares Outstanding (Basic) | 1.4M | 4.9M | 4.2M | 27.3M | 2.7M | 16.2M | 4.2M | 7.6M |
| Shares Outstanding (Diluted) | 1.4M | 4.9M | 4.2M | 27.3M | 21.6M | 16.2M | 4.2M | 7.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |